Single-agent high-dose melphalan salvage therapy for Hodgkin's disease: Cost, safety, and long-term efficacy
Open Access
- 1 December 1997
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 8 (12) , 1277-1279
- https://doi.org/10.1023/a:1008268027332
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- High-dose intravenous melphalan: a review.Journal of Clinical Oncology, 1995
- High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factorsBlood, 1995
- High-dose chemotherapy and autologous bone marrow transplantation for malignant lymphomasCancer Treatment Reviews, 1995
- High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Long term follow-up in 128 patientsAnnals of Oncology, 1993
- The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight- year study of 155 patientsBlood, 1993
- Autologous transplantation in poor risk Hodgkin's disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescueBritish Journal of Cancer, 1993
- High-dose chemotherapy and autologous bone marrow transplantation for relapsed and refractory Hodgkin's diseaseEuropean Journal Of Cancer, 1992
- Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantationBlood, 1989
- Regimen-related toxicity in patients undergoing bone marrow transplantation.Journal of Clinical Oncology, 1988
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958